Involving Blood Clotting Factor (e.g., Involving Thrombin, Thromboplastin, Fibrinogen, Etc.) Patents (Class 435/13)
  • Patent number: 11229688
    Abstract: The present invention is directed to compounds, methods for stabilizing thrombin activity with a thrombin binding oligonucleotide and to stabilized thrombin. The thrombin binding oligonucleotide is capable of inhibiting thrombin activity whereby the inhibition can be reversed with an antisense oligonucleotide.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: January 25, 2022
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Yair Pilpel, Sivan Doron, Yuri Zherdev, Tamara Byk-Tennenbaum
  • Patent number: 11226328
    Abstract: A method of detecting a clot in a measurement chamber of a liquid sample analyzer, the liquid sample analyzer comprising one or more analyte sensors, each one of the one or more analyte sensors being arranged for measuring a physical parameter for a respective analyte in a liquid sample in the measurement chamber, wherein detection is performed after conclusion of a rinsing procedure with a primary solution (Cal2) having a pre-determined primary composition with a primary level of the analyte, the method comprising the steps of: (a) at least partly filling the measurement chamber with a secondary solution (Rinse/Cal1) having a pre-determined secondary composition with a respective secondary level for each of the analytes, wherein the respective secondary level is different from the respective primary level; (b) immediately after filling the measurement chamber with the secondary solution (Rinse/Cal1), obtaining an initial measurement result by each of the one or more analyte sensors; (c) flushing the measurem
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: January 18, 2022
    Assignee: Radiometer Medical ApS
    Inventors: Peter Aage Frischauf, Michael Taagaard, Flemming Aas
  • Patent number: 11187710
    Abstract: In some embodiments, the invention provides an in vitro method for identifying a patient as likely as likely to require a transfusion of at least six units of blood in six hours or less. The method comprise, consists essentially of, or consists of (a) analyzing a sample of blood from a patient with a viscoelastic analysis assay to obtain a coagulation characteristic value that is independent of time of the patient; and (b) comparing the coagulation characteristic value of the patient to a coagulation characteristic value that is independent of time of a control, wherein the coagulation characteristic value of the patient that is lower than the coagulation characteristic value of the control identifies the patient as likely to require a transfusion of at least six units of blood in six hours or less.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: November 30, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventor: Michael P. Chapman
  • Patent number: 11181534
    Abstract: Compositions and methods useful for point of care testing for hemophilia by measuring coagulation factor levels are provided.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: November 23, 2021
    Assignee: Bloodworks
    Inventors: Jill Marie Johnsen, Barbara A. Konkle
  • Patent number: 11172861
    Abstract: Examples described herein include detection devices and systems which may provide monitoring in accordance with an analysis mode which may be selected in accordance with a severity of disease of the user. Analysis modes used by detection devices described herein may further be changed in accordance with user and/or environmental conditions.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: November 16, 2021
    Assignee: Nihon Kohden Corporation
    Inventors: Norihito Konno, Fumiyuki Matsumura, Hirohiko Ikeya
  • Patent number: 11169161
    Abstract: The present invention relates to device (10) for determining a fibrinogen level (20) in a sample (22) comprising, a first input for obtaining an attenuance signal (24) over time indicative of a fibrin polymerization of said sample (22), a second input for obtaining a reactant concentration signal (28) over time indicative of a reactant concentration in said sample (22), wherein the reactant is any substance leading to the cleavage of fibrinogen to fibrin, a simulation unit (16) running a model (32) using the reactant concentration signal (28) as an input to provide a simulated attenuance signal (34) over time, and an evaluation unit (18) configured to infer the fibrinogen level (20) of said sample (22) by comparing the attenuance signal (24) over time with the simulated attenuance signal (34) over time.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: November 9, 2021
    Assignee: KONINKLIJKE PHILIPS N.V.
    Inventors: Hendrik Jan van Ooijen, Bart Jacob Bakker, René van den Ham
  • Patent number: 11169141
    Abstract: The invention relates to a method of detecting a clot in a measurement chamber of a liquid sample analyzer, wherein the liquid sample analyzer comprises at least two analyte sensors, a first analyte sensor, for measuring a first analyte in a liquid sample, and one or more second analyte sensors, for measuring one or more second analytes in the liquid sample in the measurement chamber, the method comprising the steps of, (a) at least partly filling the measurement chamber with a known solution having a composition comprising the first analyte at a pre-determined level, and the second one or more analytes at pre-determined levels, (b) obtaining a first sequence of measurement results by the first analyte sensor, and simultaneously obtaining a second sequence of measurement results by the second, one or more analyte sensors, (c) determining a change of the first sequence of measurement results, (d) determining a change of the second one or more sequence of measurement results, (e) comparing the change of the fir
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: November 9, 2021
    Assignee: Radiometer Medical ApS
    Inventors: Michael Taagaard, Peter Aage Frischauf, Flemming Aas
  • Patent number: 11162957
    Abstract: A blood analyzing method includes optically measuring a first calibration sample prepared from a fibrin/fibrinogen degradation product (FDP) measurement reagent and a first calibrator containing D-dimer (DD) and having a first value relating to the ratio of the content of FDP to the content of DD, acquiring first calculation data based on temporal change of optical information of the first calibration measurement sample, performing optical measurement of a second calibration measurement sample prepared from FDP measurement reagent and a second calibrator containing DD and having a second value that is different from the first value, acquiring second calculated data based on a temporal change in optical information of the second calibration measurement sample, and acquiring calibration curve information indicating the relationship between the calculation data and the value relating to the amount of DD.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: November 2, 2021
    Assignee: Sysmex Corporation
    Inventor: Junki Hayasaki
  • Patent number: 11150253
    Abstract: Disclosed is a method for analyzing a blood specimen, including the steps of: coagulating a blood specimen in the presence of an activating agent for fibrinolytic system to acquire a coagulation waveform; and acquiring information about fibrinolytic capacity of the blood specimen based on the acquired coagulation waveform.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: October 19, 2021
    Assignees: SYSMEX CORPORATION, PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY
    Inventors: Midori Shima, Keiji Nogami, Tomoko Matsumoto, Sho Shinohara, Nobuo Arai
  • Patent number: 11110416
    Abstract: A device for collecting a biological sample from a semi-solid surface. The device has a shaft with a proximate end and a distal end and a tip integrated with the shaft at the proximate end. The tip has a surface adapted to collect microorganisms thereon or release microorganism from, or both, wherein the adapted surface comprises at least one feature of a recess or extension to increase surface area of the tip and collect microorganisms thereon. Examples of such features include microfeatures with dimensions of about 1000 ?m or less. Other examples include a pipette tip.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: September 7, 2021
    Assignee: BECTON, DICKINSON AND COMPANY
    Inventors: Timothy Mark Wiles, Dwight Livingston, Jennifer Singelyn, William Alan Fox, Brian Reuben Langhoff, Vikram Patel, Sean Tucker, Ming-hsiung Yeh, Michael A. Brasch
  • Patent number: 10976323
    Abstract: The present invention provides methods for measuring the absolute concentration of Tau, and other protein, peptide fragments and proteoforms in CSF and plasma samples collected from a subject. Such biomolecules may be implicated in one or more neurological and neurodegenerative diseases or disorders. Also provided is a method for determining whether a therapeutic agent affects the CSF or plasma concentration of a central nervous system derived biomolecule. Also provided are kits for performing the methods of the invention.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: April 13, 2021
    Assignee: C2N Diagnostics LLC
    Inventors: Kristopher Michael Kirmess, Kevin Edward Yarasheski, Matthew R. Meyer
  • Patent number: 10976305
    Abstract: Provided herein are methods for generating an estimated coagulation test result from an underfilled sample tube.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: April 13, 2021
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Jonathan Miller, Adam Cloe, Krzysztof Mikrut
  • Patent number: 10969397
    Abstract: Test strips for determining the activity of a coagulation factor in a blood sample are provided. The strip comprises a support, a sample inlet port for deposition of a blood sample, and a reaction area comprising a blood coagulation reagent. The sample inlet port is connected to the reaction area, and the coagulation reagent comprises blood plasma deficient in the coagulation factor for which activity is to be measured, an ionic citrate source an ionic calcium source, and either one or more coagulation contact phase activator reagents and phospholipids or a mixture of tissue factor and phospholipids. The disclosure further relates to in vitro methods for measuring an activity of a coagulation factor.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: April 6, 2021
    Assignee: CGT ENTERPRISES, LLC
    Inventors: Bernat Galmés Sureda, Mariana Isabel Canaro Hirnyk, Vicente R. Cortina Giner
  • Patent number: 10954549
    Abstract: In some embodiments, the invention provides methods for detecting and/or classifying an anticoagulant at a therapeutically relevant amount or higher in a patient, including subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of a Factor Xa reagent to obtain a control clotting measurement; and subjecting a sample of a blood component from a patient suspected of having the anticoagulant to the clotting assay in the presence of the Factor Xa reagent to obtain a patient clotting measurement, wherein the patient clotting measurement sample greater than the control clotting measurement indicates the presence of the anticoagulant at a therapeutically relevant amount or higher in the patient. In some embodiments, the invention includes methods for classifying an anticoagulant as an anti-Factor Xa or a direct thrombin inhibitor anticoagulant using a clotting assay in the presence of an ecarin reagent.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: March 23, 2021
    Assignee: Haemonetics Corporation
    Inventors: Fowzia S. Zaman, Marc Doubleday
  • Patent number: 10942191
    Abstract: There is provided a sensor and the like which can detect a first substance with high accuracy. A sensor for detecting whether an analyte contains a first substance, includes a base and a detection section including a second substance immobilized on a surface of the base. The second substance includes an amino acid, a bond which can be cleaved by a reaction with an enzyme, and a first compound which is bonded to the amino acid by the bond and includes a first group capable of bonding to other substances, and the analyte is configured to be introduced to the detection section by being contacted with a third substance which generates the enzyme by a reaction with the first substance.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: March 9, 2021
    Assignees: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, KYOCERA CORPORATION
    Inventors: Hiroyasu Tanaka, Hideharu Kurioka, Shinsuke Sando
  • Patent number: 10908170
    Abstract: Disclosed is a method for measuring a clotting time, including the steps of: (A) mixing a blood sample, an activator, a phospholipid, and a nickel ion-forming compound to obtain a specimen; and (B) mixing the specimen obtained in step (A) with a calcium salt to prepare a measurement specimen and measuring the clotting time of the measurement specimen.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: February 2, 2021
    Assignees: SYSMEX CORPORATION, SCHOOL JURIDICAL PERSON HIGASHI-NIPPON-GAKUEN
    Inventors: Osamu Kumano, Haruki Yamaguchi, Takeshi Suzuki, Masahiro Ieko
  • Patent number: 10900979
    Abstract: The invention generally relates to methods of testing the effectiveness of a von Willebrand factor (VWF) in treating von Willebrand disease (VWD) in a subject comprising measuring VWF cleavage fragments in a blood sample from the subject before and after treatment. In particular, the invention relates to methods of measuring VWF cleavage fragments, wherein an increase in VWF cleavage fragments after the treatment indicates that endogenous a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in the subject is cleaving the VWF and wherein a decrease or absence of VWF cleavage fragments after the treatment indicates that endogenous ADAMTS13 in the subject is not cleaving the VWF.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: January 26, 2021
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • Patent number: 10877052
    Abstract: What is described is a kit for preparing a liquid thromboplastin reagent for a prothrombin time assay. The kit simplifies and minimizes reagent preparation time and is stable for 2-5 years.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: December 29, 2020
    Assignee: Instrumentation Laboratory Company
    Inventors: Kevin M. Cawthern, Ralph E. Bottenus, Chun Kung
  • Patent number: 10858689
    Abstract: Disclosed are methods and systems for the analysis activity of enzyme disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in a sample. The methods and systems disclosed herein can be useful for diagnosis of thrombotic thrombocytopenic purpura in a patient.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: December 8, 2020
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Russell Philip Grant, Christopher Michael Shuford, Meghan Norris Bradley
  • Patent number: 10852312
    Abstract: A determination method of a blood sample may include: measuring, with a first coagulation time measurement reagent and a second coagulation time measurement reagent which contain phospholipids at different concentrations, coagulation times of a blood sample of a subject, coagulation times of a normal blood sample, and coagulation times of a mixed sample including the blood sample of the subject and the normal blood sample; acquiring a first index value and a second index value based on the coagulation times; and determining whether the blood sample of the subject is a blood sample containing a direct anticoagulant based on the first index value and the second index value.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: December 1, 2020
    Assignee: SYSMEX CORPORATION
    Inventor: Osamu Kumano
  • Patent number: 10843185
    Abstract: Embodiments of a platelet testing system include an analyzer console device and a blood testing cartridge configured to releasably install into the console device. The cartridge device is configured with one or more measuring chambers and one or more mixing chambers that are fluidically connected within the cartridge device that enable the mixing of saline and a blood sample to a desired dilution. Additionally, the cartridge device is further configured with a cartridge slider that provides a reagent bead to the saline and blood mixture at a desired time. As such, one or more platelet activation assays can be conducted by measuring, through cartridge electrodes of the cartridge device, the detectable changes in platelet activity within the blood and saline mixture.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: November 24, 2020
    Assignee: CA CASYSO GMBH
    Inventors: Michael M. Gorin, Robert S. Hillman, Cory Lee McCluskey, Hubert Martin Schwaiger
  • Patent number: 10786553
    Abstract: The present invention relates to improved clotting compositions for producing high quality blood serum samples for analyte testing, such as for pathology testing and other biological assays. In particular, the present invention relates to the use of prothrombin activators in combination with stabilizing agents such as colloids for producing high quality blood serum samples. The present invention also relates to associated methods for preparing clotting compositions, tubes, kits and methods of diagnosis, prognosis and monitoring for responsiveness to therapy.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: September 29, 2020
    Assignee: Q-SERA PTY LTD.
    Inventors: Paul Masci, Kong-Nan Zhao, Martin Lavin, John De Jersey, Goce Dimeski
  • Patent number: 10725018
    Abstract: Hand-held optical thromboelastographic sensor and method of using the same for simultaneous assessment of multiple parameters of blood coagulation at a point-of-care. The sensor includes an optical system registering laser speckle intensities associated with portions of a blood sample delivered through a fluid switch to analysis chambers of a cartridge of the sensor, and data-processing circuitry programmed to derive the multiple parameters from speckle intensity. The circuitry may be part of a mobile device configured to operate without communication with a central server and/or data storage.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: July 28, 2020
    Assignee: The General Hospital Corporation
    Inventors: Seemantini K. Nadkarni, Zeinab Hajjarian, Markandey Tripathi, Diane Tshikudi
  • Patent number: 10690670
    Abstract: The invention provides assay methods of detecting plasma protease CI inhibitor (Cl-INH) that binds plasma kallikrein, Factor XII, or both, and uses thereof for identifying subjects at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: June 23, 2020
    Assignee: Dyax Corp.
    Inventors: Kusumam Joseph, Allen P. Kaplan
  • Patent number: 10620205
    Abstract: The invention features a method of monitoring a clotting process by measuring a signal characteristic of the NMR relaxation of water in a sample undergoing endotoxi-induced clotting to produce NMR relaxation data and determining from the NMR relaxation data a magnetic resonance parameter of water in the sample characteristic of the level of endotoxin present in the sample.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: April 14, 2020
    Assignee: T2 Biosystems, Inc.
    Inventors: Rahul K. Dhanda, Vyacheslav Papkov, Thomas Jay Lowery, Jr.
  • Patent number: 10588950
    Abstract: The disclosure provides compositions and methods for counteracting the effects of direct activated Factor X (FXa) inhibitors in a subject by administering a variant of FXa.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: March 17, 2020
    Assignee: PFIZER INC.
    Inventors: Debra D. Pittman, Rodney M. Camire, Joachim Fruebis
  • Patent number: 10578567
    Abstract: Methods are described for quantifying an amount of natural rubber in a plant from a sample of the plant by obtaining a T1 spin-lattice relaxation rate or T2 spin-spin relaxation rate from a NMR apparatus, such as a low-field NMR apparatus operating at a magnetic field strength of 2 T or less. The NMR relaxation rates obtained from the plant sample are compared to reference relaxation data or plots. The plots can represent the weight percent polyisoprene versus T1 spin-lattice relaxation rate or T2 spin-spin relaxation rate. The reference relaxation data or plots are generated from testing the same type of plant as the sample.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: March 3, 2020
    Assignee: Bridgestone Corporation
    Inventors: Michael C. Davis, Yingyi Huang
  • Patent number: 10578628
    Abstract: The present invention relates to a method for acquiring information on a cause of prolongation of coagulation time. The present invention also relates to a device, a system and a computer program for analyzing blood coagulation.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: March 3, 2020
    Assignees: SYSMEX CORPORATION, SCHOOL JURIDICAL PERSON HIGASHI-NIPPON-GAKUEN
    Inventors: Masahiro Ieko, Osamu Kumano, Haruki Yamaguchi, Takeshi Suzuki
  • Patent number: 10465230
    Abstract: The present invention relates to a method for in vitro determining generation of a haemostasis factor such as thrombin and/or plasmin in a test sample using a chemiluminescent substrate specific for said blood clotting factor. Upon cleavage of the substrate, a luminescent signal is generated with the aid of a luciferase. The invention also relates to a kit for in vitro determining generation of a haemostasis factor in a test sample, and to novel chemiluminescent substrates for the determination of thrombin and plasmin.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: November 5, 2019
    Assignee: STICHTING KATHOLIEKE UNIVERSITEIT
    Inventors: Waander Laurens Van Heerde, Richard Hendrik Blaauw
  • Patent number: 10383915
    Abstract: Methods and systems for releasing growth factors are disclosed. In certain embodiments, a blood sample is exposed to a sequence of one or more electric pulses to trigger release of a growth factor in the sample. In certain embodiments, the growth factor release is not accompanied by clotting within the blood sample.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: August 20, 2019
    Assignee: GENERAL ELECTRIC COMPANY
    Inventors: Vasile Bogdan Neculaes, Andrew Soliz Torres, Antonio Caiafa, Brian Dun-Lan Lee, Allen Lawrence Garner
  • Patent number: 10337048
    Abstract: The present invention concerns diagnostic methods for coagulation testing involving determining anticoagulant activity elicited by a first anticoagulant in a sample comprising measuring a first Factor Xa activity in a body fluid test sample of said subject, measuring a second Factor Xa activity in at least one calibrator sample comprising a predefined anticoagulation activity for a second anticoagulant, calculating an universal parameter for the anticoagulation activity comprised in the test sample based on the first and the second measured Factor Xa activities and comparing the said parameter for the anticoagulation activity with predefined ranges of expected anticoagulation activity for at least three anticoagulants. Further provided is a computer program code assisting the method as well as a system for carrying out the said method as well as a kit.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: July 2, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Friedrich Ackermann, Andreas Calatzis
  • Patent number: 10315140
    Abstract: A substrate for use in a filter media including, for example, in a hydrocarbon fluid-water separation filter; methods of identifying the substrate; methods of making the substrate; methods of using the substrate; and methods of improving the roll off angle of the substrate. In some embodiments, the substrate includes a hydrophilic group-containing polymer or a hydrophilic group-containing polymer coating.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: June 11, 2019
    Assignee: DONALDSON COMPANY, INC.
    Inventors: Bradly G. Hauser, Stephen K. Sontag, Davis B. Moravec, Stuti S. Rajgarhia, Andrew J. Dallas, Vijay K. Kapoor, Aflal Rahmathullah, Charles S. Christ, Joseph M. Block
  • Patent number: 10295555
    Abstract: A signal reference value (SLocal) is set at which a blood coagulation reaction time (T) of a blood coagulation time reference sample measured on the basis of the result of comparing a signal value (amount of transmitted light, amount of scattered light, amount of fluorescence, or turbidity) pertaining to blood coagulation time that varies temporally according to the mixing and reaction of the blood coagulation time reference sample and a reagent and a signal reference value (S) corresponds to an expected value (Te) for the blood coagulation reaction time that has been set beforehand so as to correspond to the blood coagulation time reference sample. As a result, it is possible to use the blood coagulation time reference sample to determine the state of the reagent and enhance the reliability of measurement results by setting a unique signal reference value for each reagent container.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: May 21, 2019
    Assignee: Hitachi High-Technologies Corporation
    Inventors: Chie Yabutani, Akihisa Makino, Shigeki Matsubara
  • Patent number: 10295552
    Abstract: Methods and kits for the diagnosis of primary hyperaldosteronism (PHA). In particular, the present invention relates to the use of a new diagnostic parameter that is composed of the ratio between the Ang II level, in particular the steady state equilibrium Ang II level, and the aldosterone level in a biological sample, such as e.g. plasma. The ratio of the two measured parameters is used to diagnose PHA in patients and has clear advantages over currently used diagnostic methods.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: May 21, 2019
    Assignee: ATTOQUANT DIAGNOSTICS GMBH
    Inventors: Marko Poglitsch, Cornelia Schwager, Dunja Van Oyen, Martin Leitner
  • Patent number: 10266871
    Abstract: It is an object of the present invention to provide a measurement method capable of easily evaluating combined effects in a single assay system, when antithrombotic agents having different mechanisms of action are used in combination. A method for measuring thrombin generation comprising: (1) a step of adding an anticoagulant, a P2Y12 receptor inhibitor, adenosine diphosphate and tissue factor to platelet rich plasma; (2) a step of adding a fluorogenic thrombin substrate and a calcium-containing solution thereto; and (3) a step of measuring fluorescence intensity.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: April 23, 2019
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yoshiyuki Morishima, Yuko Honda
  • Patent number: 10188302
    Abstract: Featured is a method for assessing risk of a patient condition. Such a method includes providing criteria that relate predetermined parameters to each other, inputting observations into given criterion and relating observations of one or more acquired parameters, and converging the given criterion so as to provide an output representative of a patient condition. Such a method further includes translating the output into a visual form such as displaying the output on a display device.
    Type: Grant
    Filed: December 26, 2012
    Date of Patent: January 29, 2019
    Assignee: The University of Vermont and State Agriculture College
    Inventors: Kathleen B. Ziedins, Christopher M. Danforth, Thomas Orfeo, Stephen J. Everse, Kenneth G. Mann
  • Patent number: 10191070
    Abstract: Disclosed are methods and systems for measuring serotonin in a sample using liquid chromatography and mass spectrometry.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: January 29, 2019
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Matthew Lee Francis Crawford, Yvonne Zamorano Wright, Russell Philip Grant
  • Patent number: 10160813
    Abstract: A molecule that binds specifically to a human tissue plasminogen activator (TPA) or a TPA mutant is provided. The molecule having sub-nanomolar affinity to inhibit fibrin-dependent plasminogen activation with an IC50<5 nM, to inhibit degradation of human fibrin clots without affecting TPA amidolytic activity or non-fibrin-dependent activation, and the amino acid sequence of the TPA mutant is at least 65% identical to SEQ ID NO: 1 or SEQ ID NO: 2. Further provided is a method for treating systemic bleeding and brain hemorrhage after TPA treatment in a patient in need of such treatment. The method comprises administering to said patient an effective amount of the molecule, wherein the molecule selectively inhibits fibrin-augmented plasminogen activation in the patient.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: December 25, 2018
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventor: Guy Reed
  • Patent number: 10132821
    Abstract: The present invention provides a processing station for automatically processing a biological sample, a system for automated real-time inventory control of consumables within a biological sample handling or assay instrument, a high throughput random access automated instrument for processing biological samples, an automated instrument for processing or analysis of a sample, and processes for automated mucoid detection and elimination. Methods of using the disclosed instruments, mucoid detection processes, and systems to process and/or analyze samples are also disclosed.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: November 20, 2018
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Rolf Silbert, David Opalsky, David Aaron Buse, Robert J. Rosati, Olev Tammer, Richard Capella, Matthias Merten
  • Patent number: 10132819
    Abstract: Disclosed is a method for measuring a clotting time, including: a mixing step of mixing a blood sample, an activator, a phospholipid, and a manganese ion-forming compound to obtain a specimen; and a measurement step of mixing the specimen obtained in the mixing step with a calcium salt to prepare a measurement specimen and measuring the clotting time of the measurement specimen, wherein the blood sample is mixed with the manganese ion-forming compound separately from the activator and the phospholipid in the mixing step.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: November 20, 2018
    Assignees: SYSMEX CORPORATION, SCHOOL JURIDICAL PERSON HIGASHI-NIPPON-GAKUEN
    Inventors: Osamu Kumano, Haruki Yamaguchi, Takeshi Suzuki, Masahiro Ieko
  • Patent number: 10060911
    Abstract: The present invention relates to a novel method for diagnosing high-affinity binders, in particular antibodies or autoantibodies, and the identification, characterization and selection of marker sequences and diagnostic use thereof, in particular in the form of a panel. The invention also relates to a singleplex assay in which the discovered selection of marker sequences is used in the form of a panel and high-affinity binders are detected using a single signal.
    Type: Grant
    Filed: August 18, 2012
    Date of Patent: August 28, 2018
    Assignee: Protagen Aktiengesellschaft
    Inventors: Stefan Müllner, Peter Schulz-Knappe, Angelika Lueking, Heike Göhler, Jessica Schwermann
  • Patent number: 9989532
    Abstract: The present invention provides a method of identifying a coagulation inhibitor in a sample, comprising: a) contacting a first portion of the sample with a substrate and thrombin; b) contacting a second portion of the sample with a substrate and a2M-thrombin (thrombin caged in alpha-2-macroglobulin); c) contacting a third portion of the sample with a substrate and coagulation factor Xa; d) contacting a fourth portion of the sample with a substrate and a2M-Xa (factor Xa caged in alpha-2-macroglobulin); and e) assaying for cleavage of the substrate in (a), (b), (c) and (d) above, wherein cleavage of the substrate in (b) and (d) and no cleavage in (a) and (c) identifies heparin in the sample; cleavage of the substrate in (a), (b) and (d) and no cleavage in (c) identifies low molecular weight heparin in the sample; cleavage of the substrate in (a) and (b) and no cleavage in (c) and (d) identifies rivaroxaban in the sample, and cleavage of the substrate in (c) and (d) and no cleavage in (a) and (b) identifies dabig
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: June 5, 2018
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Dougald Monroe, Jen-Yea Chang
  • Patent number: 9970046
    Abstract: Provided is a method of measuring blood coagulation time, the method being capable of LA detection easily and with high sensitivity as compared with the method recommended by the ISTH, without being affected by deficiency of blood coagulation factors even in a blood sample of a warfarin taker, a person who suffers from vitamin K deficiency, or a hepatic failure patient. Disclosed is a method of measuring the blood coagulation time to detect lupus anticoagulant, the method including adding a buffer solution composition containing blood coagulation factors to a blood sample before measurement or at the time of measurement of the blood coagulation time, and measuring the blood coagulation time.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: May 15, 2018
    Assignees: SCHOOL JURIDICAL PERSON HIGASHI-NIPPON-GAKUEN, SEKISUI MEDICAL CO., LTD.
    Inventors: Masahiro Ieko, Chizuru Morikawa, Keiko Hattori
  • Patent number: 9949473
    Abstract: A device and kit and method for controlling coagulation in a blood sample. The coagulation controlling agent is at least one of citrate, a protamine salt, its homologs and derivatives, benzamidine, or para-aminobenzamidine. Additives such as water soluble polymers and sugars are also contemplated. The device and kit comprise a container that contains an effective amount of thrombin and a coagulation controlling agent. The method combines thrombin and a coagulation controlling agent to stabilize thrombin or accelerate its activity in a blood sample.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: April 24, 2018
    Assignee: Becton, Dickinson and Company
    Inventors: Dougald Monroe, Shabazz Novarra, Randal Alan Hoke, Paul F. Holmes, Justyna Dudaronek
  • Patent number: 9938353
    Abstract: Embodiments herein report compositions of alpha-1 antitrypsin fusion polypeptides or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating a construct of use in pharmaceutically acceptable compositions to treat a subject in need of alpha-1 antitrypsin therapy or treatment. In other embodiments, compositions and methods disclosed herein concern linking alpha-1 antitrypsin or derivative thereof to an immune fragment.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: April 10, 2018
    Assignee: The Regents of the University of Colorado, a Body Corporate
    Inventors: Charles Dinarello, James D Crapo, Soohyun Kim
  • Patent number: 9835635
    Abstract: Disclosed is a method for measuring clotting time including: preparing a measurement sample by mixing a blood specimen suspected to contain a lupus anticoagulant, an activator, and a divalent-metal-ion-producing compound for facilitating formation of a phospholipid-containing complex; and measuring a clotting time after adding, to the measurement sample, an aqueous solution of a calcium salt as a coagulation initiator.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: December 5, 2017
    Assignees: SCHOOL JURIDICAL PERSON HIGASHI-NIPPON-GAKUEN, SYSMEX CORPORATION
    Inventors: Osamu Kumano, Haruki Yamaguchi, Takeshi Suzuki, Masahiro Ieko
  • Patent number: 9828584
    Abstract: The present invention relates to the in vitro production of erythrocytes/granulocytes and to the treatment of myelodysplastic syndrome using a method for inducing hemoblast differentiation. The present invention provides a media composition comprising gelsolin as an active ingredient for inducing the differentiation of hematopoietic precursor cells into erythrocytes/granulocytes, and a pharmaceutical composition comprising gelsolin as an active ingredient for treating myelodysplastic syndrome. Since the composition of the present invention improves the efficiency of differentiation of hematopoietic precursor cells into erythrocytes/granulocytes while maintaining a low rate of occurrence of cell dysplasia and having the effect of improving the enucleation rate and cell survivability, the present invention can be effectively used for producing erythrocytes/granulocytes in vitro and for treating myelodysplastic syndrome.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: November 28, 2017
    Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY
    Inventors: Eun Jung Baek, Eun Mi Lee
  • Patent number: 9778272
    Abstract: Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Ib? having at least two of a G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Ib? and von Willebrand factor.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: October 3, 2017
    Assignees: Blood Center Research Foundation, The Medical College of Wisconsin, Inc.
    Inventor: Robert Montgomery
  • Patent number: 9778254
    Abstract: A system and method wherein components of a reagent such as labeled antibodies are separated from a biologically active sensor surface by depositing the reagent on a carrier surface distinct from a sensor surface in a detection region. The present device provides a short, well-defined and controlled, pre-incubation time between the particles of interest in the sample fluid and the reagent, thereby increasing the reproducibility by providing all components in one detection region such as a detection chamber.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: October 3, 2017
    Assignees: KONINKLIJKE PHILIPS N.V., CONCATENO UK LIMITED
    Inventors: Femke Karina De Theije, Thea Van Der Wijk, Albert Hendrik Jan Immink, Eduard Gerard Marie Pelssers, Wilhelmina Maria Hardeman, Sandra Marlin, Gordon Thomas Jowett
  • Patent number: 9744185
    Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: August 29, 2017
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Yaron Ilan, Maya Margalit